Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy
SHANGHAI, Oct 21, 2024 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, todayMore…